Willow Review
GLP-1 tablets at the same price as injections, what Willow actually costs, and the advertising ruling you should know about.
Last updated · Read our methodology
- Rare oral semaglutide option — daily sublingual dissolving tablets for injection-averse patients
- Tablet and injection offered at the same price — no premium for avoiding needles
- Licensed U.S. doctor oversight with unlimited messaging
- Flexible: pause, taper, or continue after 90 days
- HSA/FSA accepted
- Transparent pricing with no hidden fees
- December 2025 NAD ruling: efficacy and weight-loss claims found unsubstantiated, Willow initially declined to comply and was referred to the FTC and state Attorneys General — it permanently discontinued the claims and NAD closed the matter in July 2026
- No published outcome data of its own — the figures used in GLP-1 marketing come from trials of different, FDA-approved products
- Willow's own disclaimer states its compounded formulations are not FDA-reviewed for safety, effectiveness or quality
- Compounded medications only — no brand-name Wegovy or Zepbound
- Sublingual absorption is less well established than injection for weight loss
- Cash-pay only — no insurance billing
| Scoring Criterion | Score / 10 |
|---|---|
| Clinical Effectiveness | 7.5 |
| Cost & Transparency | 6.5 |
| Program Comprehensiveness | 8.5 |
| Accessibility & Convenience | 7.0 |
| Customer Satisfaction | 8.0 |
What They Offer
Willow is a 100% online, medically supervised weight loss program that distinguishes itself by offering both injectable and oral GLP-1 medications. Their oral semaglutide comes as a daily sublingual tablet that dissolves under the tongue and absorbs directly into the bloodstream — a genuine alternative for patients who cannot or will not self-inject. After completing an online assessment, a licensed U.S. doctor reviews your health history, creates a personalized treatment plan, and prescribes medication with ongoing care and support. Both semaglutide and tirzepatide are available in either format, at the same monthly price.
How Much Willow Costs
Willow prices by medication, not by delivery method — which is the most useful thing to know about it. The tablet costs exactly the same as the injection. Most providers treat oral formulations as a premium product; Willow does not.
| Treatment | Price | Format |
|---|---|---|
| Compounded semaglutide | $299/mo | Weekly injection |
| Semaglutide tablets | $299/mo | Daily dissolvable tablet — same price |
| Compounded tirzepatide | $399/mo | Weekly injection |
| Tirzepatide tablets | $399/mo | Daily dissolvable tablet — same price |
Shipping is free, prescriptions are issued same-day after review, and HSA and FSA cards are accepted. Prices verified directly from Willow's own treatment pages on 2026-08-12. An earlier version of this review quoted a range up to $549/mo; no such price appears on Willow's site and we have removed it.
Is Willow Legit? The Advertising Ruling, and How It Ended
Willow Health Services is a real company, prescribing through licensed U.S. doctors, and patients receive medication. But anyone searching whether Willow is legitimate deserves the full sequence: a serious advertising ruling in December 2025, and its resolution in July 2026.
Novo Nordisk challenged Willow's advertising before the National Advertising Division, the advertising industry's self-regulatory body run by BBB National Programs. On December 4, 2025, NAD found that Willow had not substantiated its express claims about health, weight loss, implied benefits, superiority, or efficacy. Willow's supporting evidence consisted of published studies on Novo Nordisk's FDA-approved semaglutide products, which NAD held were insufficient to validate claims for compounded alternatives that "differ in active pharmaceutical ingredient, formulation, and method of administration."
Willow declined to comply, stating that it "maintains that the challenged advertising is truthful and can be substantiated, and therefore does not at this time agree to comply with NAD's recommendations." Because no compliance statement was given, NAD referred Willow Health to regulatory authorities, including the Federal Trade Commission and the relevant state Attorneys General.
That referral has since been resolved, and this is the part most write-ups still miss. Willow returned to NAD after discussion with the FTC, and NAD reopened the matter. On July 24, 2026, NAD announced that Willow had permanently discontinued all of the challenged claims, and that it would treat those claims, for compliance purposes, as though NAD had recommended they be discontinued. The case is closed.
Read this proportionately, in both directions. NAD is a self-regulatory body, not a government agency, and this was always a ruling about advertising substantiation — not a finding that anyone was harmed or that the medication is unsafe. Willow no longer stands as a company refusing to comply, and describing it that way today would be wrong. Equally, Willow resolved this by withdrawing the claims, not by substantiating them: nothing here establishes that its compounded tablets produce the results the old marketing implied. Read the original decision and the reopened decision at BBB National Programs — December 2025 and July 2026.
What's Included
- Licensed U.S. doctor consultation and ongoing oversight
- Compounded semaglutide (injectable or oral sublingual tablet)
- Choice of weekly injection or daily dissolvable tablet at no price difference
- Unlimited messaging with your Willow doctor
- Flexibility to pause, taper, or continue after program
- Home delivery of medications
Eligibility
BMI 30+ OR BMI 27+ with a weight-related health condition. Must be 18+. Check Willow's site for current state availability. Standard GLP-1 contraindications apply.
Clinical Results & Effectiveness
Willow has published no clinical outcome data of its own. The evidence it points to consists of trials of Novo Nordisk's FDA-approved semaglutide products — the STEP programme, where participants lost roughly 15% of body weight.
That number should not be transferred to Willow's products, and this is the specific point the December 2025 NAD ruling turned on. The trials tested a particular FDA-approved formulation delivered by injection. Willow's tablets are a compounded sublingual formulation that differs in active pharmaceutical ingredient, formulation and route of administration, and how much drug actually reaches the bloodstream by that route is not established by those trials. NAD found this reasoning insufficient; so do we. An earlier version of this review repeated it, listing "~15%" as Willow's average weight loss. That was wrong and has been removed.
Oral GLP-1 delivery is not inherently implausible — Rybelsus is an FDA-approved oral semaglutide tablet. But Rybelsus is a specific approved product with its own trial programme and a formulation designed for gastrointestinal absorption; it is not evidence for a different compounded sublingual product. For what the underlying evidence does and does not support, see our explainer on how GLP-1 medications work and our guide to oral GLP-1 options.
Willow's own site carries a disclaimer stating that its compounded formulations have not been reviewed or approved by the FDA for safety, effectiveness, quality, or therapeutic equivalence. That disclaimer is accurate, and it is the most honest sentence in its marketing.
Customer Experience
Patient feedback on third-party review sites is generally positive, with recurring praise for how quickly Willow's doctors respond to messages and for the tablet option among people who will not inject. Recurring complaints centre on shipping delays during busy periods. We do not publish an aggregate review score here: third-party review counts move constantly and are easy to misrepresent, and given the December 2025 finding about Willow's marketing claims, we are not inclined to pass along unverified numbers on its behalf.
Frequently Asked Questions
How much does Willow GLP-1 cost?
Willow charges $299/mo for semaglutide and $399/mo for tirzepatide. The price is the same whether you take it as a weekly injection or as a daily dissolvable tablet, which is unusual — most providers charge a premium for the oral form. HSA and FSA cards are accepted and shipping is free.
Does Willow really offer GLP-1 tablets instead of injections?
Yes, and it is Willow's genuine differentiator. Both semaglutide and tirzepatide are offered as dissolvable tablets as well as injections, at the same monthly price. The tablets need no refrigeration, which makes travel simpler. Note that these are compounded sublingual formulations, not Rybelsus or the FDA-approved oral semaglutide — a different product, absorbed differently.
Is Willow GLP-1 legit?
Willow Health Services is a real company using licensed U.S. doctors, and patients do receive medication. But there is a significant advertising ruling you should know about: on December 4, 2025, the National Advertising Division found that Willow had not substantiated its claims about health benefits, weight loss, superiority or efficacy. Willow declined to comply at the time, stating its advertising is truthful, and NAD therefore referred the company to the FTC and state Attorneys General. That referral has since been resolved: Willow returned to NAD, permanently discontinued the challenged claims, and NAD closed the matter on July 24, 2026. NAD is the advertising industry's self-regulatory body, so this concerns marketing substantiation rather than a government finding about drug safety — and note that Willow resolved it by withdrawing the claims, not by proving them.
How much weight will I lose on Willow?
Nobody can honestly tell you, and be sceptical of any site that quotes a percentage. The well-known figures — around 15% body weight on semaglutide — come from trials of Novo Nordisk's FDA-approved products, not compounded sublingual tablets, which differ in formulation and how they are absorbed. This exact leap is what the NAD ruling was about. Willow has published no trial data of its own.
Does Willow take insurance?
No. Willow is cash-pay. HSA and FSA cards are accepted, which is the main way to reduce the effective cost.
Are Willow's medications FDA-approved?
No. Willow prescribes compounded formulations, and its own disclaimer states they have not been reviewed or approved by the FDA for safety, effectiveness, quality, or therapeutic equivalence. Compounded drugs are legal to prescribe but are not FDA-approved finished products. If FDA-approved medication matters to you, you want a provider prescribing brand-name Wegovy or Zepbound.
Our Verdict
Willow does one thing better than almost anyone: it sells GLP-1 tablets at the same price as the injection. $299 for semaglutide, $399 for tirzepatide, whichever format you choose. Most providers treat the oral form as a premium upsell, and for someone whose real barrier is the needle, paying no penalty to avoid it is a genuine and fairly priced advantage.
What holds this at 6.0 is not the product but the company's posture toward evidence. Willow has no outcome data of its own, its marketing leaned on trials of a different, FDA-approved product, and when the National Advertising Division said that was not good enough, Willow declined to comply and was referred to the FTC and state Attorneys General. It did eventually come back and permanently discontinue those claims, closing the matter in July 2026 — which is worth real credit, and is why this is not scored lower. But it resolved the case by removing the claims, not by producing evidence for them. Its own disclaimer concedes its formulations are not FDA-reviewed. None of that means the medication does not work — it means nobody has shown that it does, at this formulation and this route.
Choose it if the tablet format is what gets you started and you understand you are buying a compounded product whose efficacy marketing is unsubstantiated. Look elsewhere if you want FDA-approved medication, published evidence, or a provider without an open regulatory referral — our ranked GLP-1 programs page covers the alternatives.
Get Started →Disclosures
Affiliate Disclosure: GLP1Authority.com may earn commissions from referrals or affiliate partnerships. This review reflects our independent assessment and does not influence our ratings.
Medical Disclaimer: This review is for informational purposes only and does not constitute medical advice. Please consult with a healthcare provider before starting any GLP-1 weight loss program.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002 (PubMed).
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
- Mayo Clinic - Semaglutide medication guide
Stay Informed
Get the GLP-1 Insider Brief
Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.
No spam. Unsubscribe any time.